IDENTIFICATION OF GENOMIC CHANGES MEDIATING MELANOMA DEVELOPMENT AND PROGRESSION

介导黑色素瘤发生和进展的基因组变化的鉴定

• 批准号: 5203427
• 负责人: JEFFREY M. TRENT
• 金额: --
• 依托单位: NATIONAL HUMAN GENOME RESEARCH INSTITUTE
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/5203427
• 关键词: carcinogenesis; chromosome aberrations; complementary DNA; gene expression; gene rearrangement; genome; human genetic material tag; human tissue; karyotype; melanoma; molecular cloning; molecular genetics; neoplasm /cancer genetics; neoplastic process; nucleic acid hybridization; subtraction hybridization; suppressor mutations

The purpose of this project continues to be the determination of the molecular basis of chromosome rearrangements underlying the genesis and progression of human malignant melanoma. Melanoma has the fastest growing rate of incidence of any cancer (next to lung cancer in women) in the Western world, and extraordinarily little is known about the molecular genetic changes underlying this important disease. This project can be divided into three component parts. 1) Molecular analysis of tumor progression. [This focuses on clonal progression identified by tissue dissection and comparative genomic hybridization, and on clonal karyotypic alterations in malignant melanoma]. 2) Identification of genes differentially expressed during growth, differentiation and progression. [This focuses on suppression of tumorigenicity of chromosome 6, cDNA subtraction/differential display, and retroviral-mediated reversion of tumor suppression]. 3) Genomic analysis of chromosome 6 alterations. [This involves microdissection-based cloning of chromosomal breakpoints in melanoma, and other malignancies].

该项目的目的仍然是确定 染色体重排的分子基础， 人类恶性黑色素瘤的进展。 黑色素瘤有最快的 任何癌症发病率的增长率（仅次于妇女肺癌） 在西方世界，人们对这一点知之甚少。 这种重要疾病背后的分子遗传变化。 这 项目可分为三个组成部分。 1)分子分析 肿瘤的发展。[This重点关注克隆进展， 组织解剖和比较基因组杂交，以及克隆 恶性黑色素瘤中的核型改变]。 2)鉴定 在生长、分化和分化过程中差异表达的基因， 进展 [This重点是抑制肿瘤的发生， 6号染色体，cDNA消减/差异显示，和 逆转录病毒介导的肿瘤抑制逆转]。 3)基因组分析 6号染色体的变异 [This包括基于显微解剖的 黑色素瘤和其他恶性肿瘤中染色体断裂点的克隆]。